The Prostate Cancer Registry collected real-world data on the clinical characteristics, management, and outcomes of more than 3000 men with metastatic castration-resistant prostate cancer (mCRPC) from 2013–2016. |
This study found that the efficacy of three major first-line treatments for mCRPC (abiraterone, enzalutamide, and docetaxel) was similar between subpopulations of patients with co-morbidities and the wider patient population. |
These real-world data provide information on long-term outcomes for patients with metastatic castration-resistant prostate cancer. |
1 Background
2 Methods
2.1 Aim, Study Design, and Setting
2.2 Patients
2.3 Variables and Data Measurement
2.4 Bias
2.5 Study Size
2.6 Statistical Methods
3 Results
3.1 Patients
3.2 Overall and First-Line mCRPC Treatment Population
3.2.1 Baseline Characteristics
Characteristic | Patients who had not received previous mCRPC treatment at baseline N = 1874 | First-line treatment with | ||
---|---|---|---|---|
Abiraterone N = 754 | Enzalutamide N = 227 | Docetaxel N = 602 | ||
Age, | ||||
Mean (SD), years | 73.1 (8.58) | 75.3 (8.20) | 74.9 (7.87) | 68.8 (7.70) |
Median (range), years | 74.0 (43–98) | 76.0 (43–98) | 76.0 (53–91) | 69.0 (44–88) |
Age group, n (%) | ||||
< 65 years | 314 (16.8) | 81 (10.7) | 24 (10.6) | 173 (28.7) |
65–74 years | 683 (36.4) | 228 (30.2) | 75 (33.0) | 280 (46.5) |
≥ 75 years | 877 (46.8) | 445 (59.0) | 128 (56.4) | 149 (24.8) |
Geographic distribution, n (%) | ||||
N | 1874 (100.0) | 754 (100.0) | 227 (100.0) | 602 (100.0) |
Austria | 12 (0.6) | 2 (0.2) | 2 (0.9) | 2 (0.3) |
Belgium | 129 (6.9) | 60 (8.0) | 25 (11.0) | 28 (4.7) |
France | 209 (11.2) | 116 (15.4) | 27 (11.9) | 53 (8.8) |
Germany | 240 (12.8) | 128 (17.0) | 19 (8.4) | 61 (10.1) |
Israel | 18 (1.0) | 11 (1.5) | 0 | 3 (0.5) |
Italy | 238 (12.7) | 157 (20.8) | 2 (0.9) | 70 (11.6) |
Luxembourg | 8 (0.4) | 1 (0.1) | 0 | 6 (1.0) |
Poland | 163 (78.7) | 1 (0.1) | 2 (0.9) | 122 (20.3) |
Portugal | 78 (4.2) | 21 (2.8) | 2 (0.9) | 43 (7.1) |
Russia | 79 (4.2) | 16 (2.1) | 2 (0.9) | 27 (4.5) |
Slovenia | 22 (1.2) | 14 (1.9) | 2 (0.9) | 1 (0.2) |
Spain | 141 (7.5) | 85 (11.3) | 17 (7.5) | 24 (4.0) |
Sweden | 149 (8.0) | 18 (2.4) | 47 (20.7) | 38 (6.3) |
Switzerland | 14 (0.8) | 6 (0.8) | 1 (0.4) | 7 (1.2) |
Turkey | 61 (3.3) | 10 (1.3) | 0 | 47 (7.8) |
United Kingdom | 313 (16.7) | 108 (14.3) | 79 (34.8) | 70 (11.6) |
ECOG performance status, n (%) | ||||
N | 1732 | 715 | 187 | 555 |
0 | 746 (43.1) | 340 (47.6) | 99 (52.9) | 211 (38.0) |
1 | 797 (46.0) | 318 (44.5) | 69 (36.9) | 293 (52.8) |
≥ 2 | 189 (10.9) | 57 (8.0) | 19 (10.2) | 51 (9.2) |
Gleason score at initial diagnosis, n (%) | ||||
N | 1713 | 674 | 208 | 574 |
≤ 6 | 216 (12.6) | 100 (14.8) | 25 (12.0) | 61 (10.6) |
7 | 548 (32.0) | 230 (34.1) | 57 (27.4) | 178 (31.0) |
8–10 | 949 (55.4) | 344 (51.0) | 126 (60.6) | 335 (58.4) |
M stage at initial diagnosis, n (%) | ||||
N | 1830 | 732 | 222 | 591 |
Mx | 353 (19.3) | 161 (22.0) | 40 (18.0) | 100 (16.9) |
M0 | 682 (37.3) | 315 (43.0) | 88 (39.6) | 195 (33.0) |
M1, M1a, M1b, M1c | 795 (43.4) | 256 (35.0) | 94 (42.3) | 296 (50.1) |
Time from initial prostate cancer diagnosis to start of the study | ||||
N | 1874 | 754 | 227 | 602 |
Median years (range) | 3.8 (0–29) | 5.0 (0–29) | 4.5 (0–24) | 2.6 (0–22) |
Presence of bone metastases (baseline), n (%) | ||||
N | 1396 | 550 | 184 | 451 |
Any | 1253 (89.8) | 548 (99.6) | 164 (89.1) | 405 (89.8) |
≥ 5 | 548 (39.3) | 203 (36.9) | 60 (32.6) | 192 (42.6) |
Visceral metastases (baseline), n (%) | ||||
N | 1484 | 612 | 163 | 517 |
Liver only | 69 (4.6) | 13 (2.1) | 9 (5.5) | 39 (7.5) |
Lung only | 96 (6.5) | 39 (6.4) | 7 (4.3) | 40 (7.7) |
Liver and lung | 17 (1.1) | 7 (1.1) | 0 | 9 (1.7) |
Biological parameters | ||||
PSA, ng/mL | ||||
N | 1833 | 733 | 226 | 588 |
Mean (SD) | 143.66 (462.496) | 125.54 (488.412) | 79.82 (173.516) | 181.05 (510.264) |
Lactic acid dehydrogenase, U/L | ||||
N | 732 | 331 | 77 | 242 |
Mean (SD) | 344.5 (296.75) | 330.3 (281.58) | 283.5 (204.28) | 367.1 (320.45) |
Hemoglobin, g/dL | ||||
N | 1618 | 651 | 199 | 530 |
Mean (SD) | 12.6 (1.67) | 12.7 (1.63) | 12.9 (1.43) | 12.5 (1.73) |
Alkaline phosphatase, U/L | ||||
N | 1365 | 575 | 191 | 414 |
Mean (SD) | 209.6 (341.29) | 192.1 (282.84) | 181.8 (473.49) | 223.7 (297.86) |
Co-morbidities requiring treatment, n (%) | ||||
Any | 1367 (72.9) | 566 (75.1) | 176 (77.5) | 398 (66.1) |
Cardiovascular | 1221 (65.2) | 504 (66.8) | 161 (70.9) | 351 (58.3) |
Hypertension | 1002 (53.5) | 411 (54.5) | 129 (56.8) | 289 (48.0) |
Angina pectoris | 115 (6.1) | 34 (4.5) | 12 (5.3) | 35 (5.8) |
Myocardial infarction | 133 (7.1) | 48 (6.4) | 21 (9.3) | 32 (5.3) |
Arrhythmia | 154 (8.2) | 62 (8.2) | 22 (9.7) | 41 (6.8) |
Thromboembolic disease | 55 (2.9) | 21 (2.8) | 8 (3.5) | 18 (3.0) |
Cerebrovascular accident | 48 (2.6) | 19 (2.5) | 3 (1.3) | 17 (2.8) |
Transient ischemic attack | 34 (1.8) | 14 (1.9) | 5 (2.2) | 9 (1.5) |
Other cardiovascular | 300 (16.0) | 139 (18.4) | 39 (17.2) | 80 (13.3) |
Respiratory | 160 (8.5) | 60 (8.0) | 27 (11.9) | 48 (8.0) |
Chronic obstructive pulmonary disease | 105 (5.6) | 41 (5.4) | 16 (7.0) | 29 (4.8) |
Other respiratory | 60 (3.2) | 20 (2.7) | 12 (5.3) | 19 (3.2) |
Renal | 143 (7.6) | 52 (6.9) | 24 (10.6) | 42 (7.0) |
Chronic renal disease | 82 (4.4) | 31 (4.1) | 16 (7.0) | 21 (3.5) |
Other renal | 62 (3.3) | 21 (2.8) | 8 (3.5) | 21 (3.5) |
Hepatic | 31 (1.7) | 17 (2.3) | 3 (1.3) | 8 (1.3) |
Chronic hepatic disease | 17 (0.9) | 9 (1.2) | 3 (1.3) | 4 (0.7) |
Other hepatic | 14 (0.7) | 8 (1.1) | 0 | 4 (0.7) |
Neurologic | 157 (8.4) | 66 (8.8) | 17 (7.5) | 41 (6.8) |
Peripheral sensory impairment | 8 (0.4) | 2 (0.3) | 0 | 5 (0.8) |
Memory impairment | 14 (0.7) | 5 (0.7) | 4 (1.8) | 2 (0.3) |
Cognitive disorder | 12 (0.6) | 4 (0.5) | 2 (0.9) | 1 (0.2) |
Convulsion | 5 (0.3) | 3 (0.4) | 0 | 0 |
Other neurologic | 54 (2.9) | 27 (3.6) | 4 (1.8) | 10 (1.7) |
Infections | 11 (0.6) | 6 (0.8) | 3 (1.3) | 1 (0.2) |
Other infection | 11 (0.6) | 6 (0.8) | 3 (1.3) | 1 (0.2) |
Diabetes mellitus | 307 (16.4) | 121 (16.0) | 47 (20.7) | 100 (16.6) |
Type 2 | 235 (12.5) | 87 (11.5) | 36 (15.9) | 82 (13.6) |
Type 1 | 72 (3.8) | 34 (4.5) | 11 (4.8) | 18 (3.0) |
Investigations | ||||
Hypercholesterolemia | 276 (14.7) | 122 (16.2) | 48 (21.1) | 62 (10.3) |
Prior treatment, n (%) | Patients who had not received previous mCRPC treatment at baseline n = 1874 | First-line treatment with | ||
---|---|---|---|---|
Abiraterone n = 754 | Enzalutamide n = 227 | Docetaxel n = 602 | ||
Orchiectomy since initial diagnosis | 123 (6.6) | 35 (4.6) | 12 (5.3) | 44 (7.3) |
Radical prostatectomy/prostate-specific radiotherapy since initial diagnosis | ||||
Both radical prostatectomy and prostate-specific radiotherapy | 160 (8.5) | 79 (10.5) | 18 (7.9) | 52 (8.6) |
Radical prostatectomy only | 190 (10.1) | 89 (11.8) | 21 (9.3) | 57 (9.5) |
Prostate-specific radiotherapy only | 399 (21.3) | 174 (23.1) | 46 (20.3) | 140 (23.3) |
None | 1125 (60.0) | 412 (54.6) | 142 (62.6) | 353 (58.6) |
Prior systemic anticancer therapy | ||||
Any | 1774 (94.7) | 718 (95.2) | 213 (93.8) | 567 (94.2) |
Endocrine therapy | 1755 (93.6) | 710 (94.2) | 211 (93.0) | 562 (93.4) |
Antiandrogen | 1569 (83.7) | 646 (85.7) | 188 (82.8) | 506 (84.1) |
GnRH agonist | 1280 (68.3) | 474 (62.9) | 211 (93.0) | 434 (72.1) |
Steroids | 194 (10.4) | 76 (10.1) | 22 (9.7) | 75 (12.5) |
GnRH antagonist | 127 (6.8) | 64 (8.5) | 9 (4.0) | 39 (6.5) |
Estrogens and derivatives | 53 (2.8) | 28 (3.7) | 7 (3.1) | 5 (0.8) |
Adrenal synthesis inhibitors | 14 (0.7) | 6 (0.8) | 0 (0) | 7 (1.2) |
Other | 6 (0.3) | 0 (0) | 3 (1.3) | 2 (0.3) |
Bone-targeted | ||||
Any | 455 (24.3) | 163 (21.6) | 32 (14.1) | 176 (29.2) |
Zoledronic acid | 330 (17.6) | 120 (15.9) | 20 (8.8) | 126 (20.9) |
Denosumab | 103 (5.5) | 45 (6.0) | 10 (4.4) | 32 (5.3) |
Other | 55 (2.9) | 9 (1.2) | 6 (2.6) | 32 (5.3) |
Other | 28 (1.5) | 12 (1.6) | 5 (2.2) | 7 (1.2) |
3.2.2 Treatment Exposure
n (%) | Abiraterone | Enzalutamide | Docetaxel |
---|---|---|---|
First treatment set | 754 | 227 | 602 |
Patients with a next therapya | 367 (48.7) | 99 (43.6) | 426 (70.8) |
Therapy | |||
Abiraterone | – | 17 (17.2) | 191 (44.8) |
Docetaxel | 178 (48.5) | 42 (42.4) | – |
Enzalutamide | 99 (27.0) | – | 116 (27.2) |
Cabazitaxel | 4 (1.1) | 2 (2.0) | 74 (17.4) |
Other chemotherapy | 10 (2.7) | 1 (1.0) | 8 (1.9) |
3.2.3 Efficacy Outcomes
Kaplan–Meier estimates (patients with no progression at end of Registry are censored) | Abiraterone | Enzalutamide | Docetaxel |
---|---|---|---|
First-line treatment population, N | 754 | 227 | 602 |
Median time to progressiona (95% CI), months | 9.6 (8.4–10.8) | 10.30 (8.9–13.0) | 7.6 (7.0–8.0) |
Patients with cardiovascular disease, N | 504 | 161 | 351 |
Median time to progressiona (95% CI), months | 9.7 (8.2–11.2) | 9.8 (8.0–12.9) | 7.4 (6.6–7.9) |
Patients with diabetes mellitus, N | 121 | 47 | 100 |
Median time to progressiona (95% CI), months | 12.0 (9.8–16.4) | 10.3 (5.5–14.7) | 7.7 (5.7–9.0) |
Patients with visceral metastases, N | 59 | – | 88 |
Median time to progressiona (95% CI), months | 6.2 (4.8–8.1) | – | 7.8 (6.7–9.9) |
Dependent variable | Unadjusted/adjusted | Comparison | Number of observations | Hazard ratio (95% CI) | p value |
---|---|---|---|---|---|
Unadjusted and adjusted treatment effect, time to progression, abiraterone vs. docetaxel (first line) | |||||
Time to progression | Unadjusted | Abiraterone vs. docetaxel | n = 1356 | 0.599 (0.529–0.678) | < 0.0001 |
Time to progression | Unadjusted | Abiraterone vs. docetaxel | n = 1049 | 0.597 (0.519–0.686) | < 0.0001 |
Time to progression | Adjusted | Abiraterone vs. docetaxel | n = 1049 | 0.685 (0.586–0.800) | < 0.0001 |
Unadjusted and adjusted treatment effect, time to progression, enzalutamide vs. docetaxel (first line) | |||||
Time to progression | Unadjusted | Enzalutamide vs. docetaxel | n = 829 | 0.548 (0.456–0.657) | < 0.0001 |
Time to progression | Unadjusted | Enzalutamide vs. docetaxel | n = 674 | 0.556 (0.455–0.678) | < 0.0001 |
Time to progression | Adjusted | Enzalutamide vs. docetaxel | n = 674 | 0.564 (0.455–0.698) | < 0.0001 |
Unadjusted and adjusted treatment effect, time to progression, abiraterone vs. enzalutamide (first line) | |||||
Time to progression | Unadjusted | Abiraterone vs. enzalutamide | n = 981 | 1.031 (0.867–1.226) | 0.7302 |
Time to progression | Unadjusted | Abiraterone vs. enzalutamide | n = 751 | 1.009 (0.833–1.222) | 0.9277 |
Time to progression | Adjusted | Abiraterone vs. enzalutamide | n = 751 | 1.040 (0.851–1.271) | 0.7000 |
Abiraterone | Enzalutamide | Docetaxel | |
---|---|---|---|
First-line treatment population, N | 754 | 227 | 602 |
Median overall survival (95% CI), months | 27.1 (25.3–28.9) | 27.1 (21.8–32.7) | 27.9 (25.6–31.5) |
Patients with cardiovascular disease, N | 504 | 161 | 351 |
Median overall survival (95% CI), months | 27.4 (23.0–30.3) | 26.1 (18.1–33.9) | 26.1 (23.0–29.7) |
Patients with diabetes mellitus, N | 121 | 47 | 100 |
Median overall survival (95% CI), months | 30.8 (21.7–NE) | 27.1 (14.7–NE) | 24.3 (16.1–29.0) |
Patients with visceral metastases, N | 59 | – | 88 |
Median overall survival (95% CI), months | 17.40 (13.60–22.70) | – | 20.40 (15.10–26.10) |
Dependent variable | Unadjusted/adjusted | Comparison | Number of observations | Hazard ratio (95% CI) | p value |
---|---|---|---|---|---|
Unadjusted and adjusted treatment effect, overall survival, abiraterone vs. docetaxel (first line) | |||||
Overall survival | Unadjusted | Abiraterone vs. docetaxel | n = 1356 | 1.035 (0.891–1.202) | 0.6520 |
Overall survival | Unadjusted | Abiraterone vs. docetaxel | n = 1049 | 0.994 (0.841–1.176) | 0.9462 |
Overall survival | Adjusted | Abiraterone vs. docetaxel | n = 1049 | 1.105 (0.920–1.328) | 0.2843 |
Unadjusted and adjusted treatment effect, overall survival, enzalutamide vs. docetaxel (first line) | |||||
Overall survival | Unadjusted | Enzalutamide vs. docetaxel | n = 829 | 1.047 (0.843–1.301) | 0.6763 |
Overall survival | Unadjusted | Enzalutamide vs. docetaxel | n = 674 | 1.064 (0.841–1.347) | 0.6039 |
Overall survival | Adjusted | Enzalutamide vs. docetaxel | n = 674 | 1.075 (0.837–1.380) | 0.5727 |
Unadjusted and adjusted treatment effect, overall survival, abiraterone vs. enzalutamide (first line) | |||||
Overall survival | Unadjusted | Abiraterone vs. enzalutamide | n = 981 | 0.983 (0.798–1.211) | 0.8741 |
Overall survival | Unadjusted | Abiraterone vs. enzalutamide | n = 751 | 0.927 (0.737–1.165) | 0.5147 |
Overall survival | Adjusted | Abiraterone vs. enzalutamide | n = 751 | 1.000 (0.788–1.270) | 0.9986 |